Rezolute, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, covering an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $93.5 million in net proceeds.

Key Highlights

  • Offering size: 22,040,976 shares of common stock priced at $3.8700 per share, plus pre-funded warrants to purchase up to 3,800,000 shares at $3.8690 per warrant.
  • Net proceeds: Approximately $93.5 million, after deducting underwriting discounts, commissions, and offering expenses payable by the company.
  • Underwriters: Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. serve as representatives of the underwriting group.
  • Expected closing: On or about November 16, 2026, subject to customary closing conditions.
  • Lock-up period: Executive officers and directors agreed not to sell or dispose of common stock for 30 days after the final prospectus supplement, subject to certain exceptions, with Morgan Stanley's written consent required to waive the restriction.
  • Pre-funded warrant exercise price: $0.001 per share, with beneficial ownership caps of 4.99% (or up to 19.99% at the holder's election) of outstanding common stock.
  • Intended use of proceeds: The company disclosed it intends to use net proceeds, together with existing cash and cash equivalents, to fund ersodetug commercialization preparation and for working capital and general corporate purposes.

Rezolute Enters Underwriting Agreement for November 2026 Public Offering

According to the filing, Rezolute, Inc. (NASDAQ:RZLT) entered into an underwriting agreement on November 13, 2026, with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. as representatives of several underwriters. The offering comprises 22,040,976 shares of common stock, par value $0.001 per share, at $3.8700 per share, and pre-funded warrants to purchase up to 3,800,000 additional shares at $3.8690 per warrant. The warrant price reflects the per-share offering price less the $0.001 per-share exercise price of each pre-funded warrant.

The company disclosed that the shares and pre-funded warrants are being offered under a registration statement on Form S-3 (File No. 333-299867), which the SEC declared effective on November 10, 2026. Estimated net proceeds to the company, after deducting underwriting discounts, commissions, and offering expenses, are approximately $93.5 million. The company stated it intends to use those proceeds, together with existing cash and cash equivalents, to fund ersodetug commercialization preparation and for working capital and general corporate purposes.

The pre-funded warrants are exercisable at any time after issuance and carry a beneficial ownership blocker preventing exercise if it would result in the holder and its affiliates owning more than 4.99% of outstanding common stock or combined voting power, unless the holder elects to raise that threshold to as high as 19.99% upon at least 61 days' notice to the company. The filing notes that pre-funded warrant holders have no voting rights or other privileges accorded to common stockholders. The underwriting agreement includes customary representations, warranties, indemnification obligations, and termination provisions, the full text of which is incorporated by reference as Exhibit 1.1.

What Was Disclosed

Rezolute disclosed the pricing terms, structure, and expected net proceeds of a November 2026 underwritten public offering of common stock and pre-funded warrants, along with the key terms of the related underwriting agreement and lock-up commitments from officers and directors.